Solara Active Pharma Sciences Limited — Updates, 05-11-2025: Press Release

Solara's Q2 FY26 performance hit by Mangalore facility shutdown for upgrade, impacting revenue (314 Cr) & EBITDA (35.2 Cr), leading to a loss (10.1 Cr). Debt reduced to 623.3 Cr. Demerger of CRAMS/Polymers business (108 Cr FY25 revenue) planned to further cut debt by 200 Cr, aiming for stronger balance sheet.